Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Postmarketing studies: benefits and risks.

F B Garfield1, J J Caro

  • 1Caro Research, Concord, MA 01742, USA. fgarfield@caroresearch.com

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ageing anaesthetist: lessons from the North American experience.

BJA education·2021
Same author

Secondary prevention fallacy: pitfalls in comparing with primary.

Expert review of pharmacoeconomics & outcomes research·2009
Same author

The design of an observational study of hypertension management, adherence and pressure control in Blood Pressure Success Zone Program participants.

International journal of clinical practice·2008
Same author

Oxybutynin extended release and tolterodine immediate release : a health economic comparison.

Clinical drug investigation·2007
Same author

Care needs and economic consequences after acute ischemic stroke: the Erlangen Stroke Project.

European journal of neurology·2005
Same author

Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.

Diabetic medicine : a journal of the British Diabetic Association·2004
Same journal

Development and Validation of a Brief Healthcare Insecurity Scale in a Sample of U.S. Adults Living with and without HIV.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

A Competency Framework for Health Technology Assessment Expertise: Results from a Delphi Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on selected Health-Related Outcomes and Costs for IBD Patients in Germany?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Interpreting the Economic Value of TPEx in Recurrent or Metastatic HNSCC: The Importance of Decision Context, Utility Timing, and Treatment Burden.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Development, use and psychometric properties of vision and hearing bolt-ons for EQ-5D-3L and EQ-5D-5L: a systematic review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles

Large postmarketing studies for statin drugs showed significant benefits, including safety and efficacy confirmation. However, short-term risks like cost-effectiveness concerns may outweigh benefits, favoring companies with a long-term perspective.

Area of Science:

  • Pharmacoeconomics
  • Clinical Research
  • Drug Development

Background:

  • Postmarketing outcomes studies are crucial for evaluating drug safety and efficacy after market approval.
  • Statin drugs, widely used for lipid lowering, have been subjects of extensive postmarketing research.

Purpose of the Study:

  • To analyze the benefits and risks associated with large-scale postmarketing outcomes studies.
  • To use statin drug studies as a case example to illustrate these benefits and risks.

Main Methods:

  • A comprehensive literature review was conducted.
  • Existing studies on statin drugs and their postmarketing outcomes were analyzed.

Main Results:

  • Benefits included definitive proof of safety and efficacy, expanded drug indications, and enhanced sponsor reputation.

Related Experiment Videos

  • Risks involved a 'coat-tail effect' benefiting all statins, initial economic analyses questioning cost-effectiveness, and slow integration into clinical practice.
  • Sponsors incurred significant costs, but the risk of data misuse by competitors did not materialize.

    • Conclusions:

    • The balance of risks and benefits in postmarketing studies is time-dependent.
    • Short-term perspectives may highlight risks, while long-term strategic views reveal substantial benefits for companies investing in large postmarketing studies.